The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InWealthfront Advisers LLC significantly increased its position in Amgen Inc. during the third quarter, raising its stake by 22.4%. The investment firm now holds 70,233 shares of Amgen, valued at an estimated $19.82 million. This move comes as Amgen reported robust fourth-quarter earnings, surpassing analyst expectations. Furthermore, the biotechnology giant demonstrated its commitment to shareholder returns by increasing its quarterly dividend to $2.52 per share. Despite a recent 3.0% dip in Amgen's stock price, Wealthfront's expanded holding suggests confidence in the company's underlying financial strength and future prospects. This strategic increase by a prominent advisory firm highlights Amgen's appeal to institutional investors.